NCT00002083已完成不适用
Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS
Advanced Peptides4 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 4
研究概览
简要总结
To compare the effects of intranasal peptide T and placebo in the treatment of painful peripheral neuropathy associated with human immunodeficiency virus (HIV) infection.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Documented HIV-1 infection.
- •CD4 count < 500 cells/mm
- •HIV-1-associated distal symmetrical polyneuropathy, with peripheral neuropathy present for at least 6 weeks prior to study entry.
- •Pain severity of at least 8 on an analog scale.
- •Prior zidovudine therapy for at least the previous 3 months (unless patient has shown intolerance to zidovudine).
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms and conditions are excluded:
- •Neuropathy due to any other cause besides HIV infection.
- •Any symptom consistent with a new or active underlying opportunistic infection or malignancy that could interfere with the evaluation of neuropathy.
- •Clinical evidence of new or active CNS disease, potentially from opportunistic infection or neoplasm resulting from HIV infections, that could interfere with the evaluation of neuropathy.
- •Other CNS disease (e.g., myelopathy) that could complicate the evaluation of neuropathy.
- •Active life-threatening illness other than AIDS.
- •Concurrent Medication:
- •Hydralazine.
- •Isoniazid (INH).
- •Current use of tricyclic antidepressants, anticonvulsants, or clonidine unless the patient has used the drug without a change in dose for at least 3 months prior to study entry.
- •Narcotics, unless the patient has been using them for at least 6 weeks prior to study entry.
- •Prior Medication:
- •ddI or ddC in the past 8 weeks.
- •Prior peptide T.
- •Prior tricyclic antidepressants, anticonvulsants, or clonidine unless they have been used for at least 3 months without change in dose.
- •Other investigational drugs within the past 30 days.
- •Zidovudine (if intolerance not demonstrated).
- •Zidovudine for at least the previous 3 months (unless patient has demonstrated intolerance to zidovudine).
- •Chronic alcohol abuse, or current abuse of psychoactive recreational drugs as defined in DSM IIIR. Patients who may be regarded as unreliable for the study.
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001PainNCT05508594Cessatech A/S220
已完成
4 期
Comparison of Postoperative Analgesia Between Intravenous Paracetamol and Intranasal TapentadolLower Limb FractureNCT05999890Kempegowda Institute of Medical Sciences, Bangalore74
撤回
不适用
Intranasal Neurostimulation for the Treatment of Neurosensory Abnormalities in CL Wearers (INTAC)Neuropathic PainContact AllergyNCT04240587Tufts Medical Center
已完成
2 期
A Single-dose Study of Intranasal Ketorolac in the Treatment of Pain Secondary to Dental Impaction SurgeryDental ImpactionPainNCT01356225Egalet Ltd80
招募中
不适用
A study to Compare the effectiveness of packing nose with two different pain relieving medicines in preventing the rise in heart rate and blood pressure during the surgical procedure and reducing pain after surgery in endoscopic surgical removal of pituitary tumors through nose.CTRI/2015/09/006216Christian Medical college100